|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Assessing liver injury associated with antimycotics:Concise literature review and clues from data mining of the FAERS database显示文摘AIM: To inform clinicians on the level of hepatotoxicrisk among antimycotics in the post-marketing setting,following the marketing suspension of oral ketocon-azole for drug-induced liver injury(DILI).METHODS: The publicly available international FAERSdatabase(2004-2011) was used to extract DILI cases(including acute liver failure events), where antimycot-ics with systemic use or potential systemic absorptionwere reported as suspect or interacting agents. The re-porting pattern was analyzed by calculating the report-ing odds ratio and corresponding 95%CI, a measure ofdisproportionality, with time-trend analysis where ap-propriate.RESULTS: From 1687284 reports submitted over the8-year period, 68115 regarded liver injury. Of these,2.9% are related to antimycotics(1964 cases, of which 112 of acute liver failure). Eleven systemic antimycotics(including ketoconazole and the newer triazole deriva-tives voriconazole and posaconazole) and terbinafine(used systemically to treat onychomicosis) generated a significant disproportionality, indicating a post-market-ing signal of risk.CONCLUSION: Virtually all antimycotics with systemic action or absorption are commonly reported in clinically significant cases of DILI. Clinicians must be aware of this aspect and monitor patients in case switch is con-sidered, especially in critical poly-treated patients under chronic treatment. | Emanuel Raschi Elisabetta Poluzzi Ariola Koci Paolo Caraceni Fabrizio De Ponti | 2014 | World Journal of Hepatology2014，6，8： | 10 |
| 2 | Endostatin and endorepellin,a common route of action for similar angiostatic cancer avengers 显示文摘 | Poluzzi C Iozzo R V Schaefer L | 2016 | Adv Drug Deliv Rev2016，97，： | 1 |
| 3 | Antibacterial macrolides:a drugs class with a complex pharmacological profile显示文摘 | Abu-Gharbieh E Vasina V Poluzzi E | 2004 | Pharmacol Res2004，50，： | 1 |
| 4 | Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes:an overview显示文摘 | de Ponti F Poluzzi E Cavalli A | 2002 | Drug Saf2002，25，4： | 1 |
| 5 | Toward a pharmacophore for drugs inducing the lon QT syndrome 显示文摘 | Cavalli A Poluzzi E De Ponti F | 2002 | J Med Chem2002，45，18： | 1 |
| 6 | Drug-induced torsades de pointes:data mining of the public version of the FDA Adverse Event Reporting System (AERS)显示文摘 | Poluzzi E Raschi E Moretti U | 2009 | Pharmacoepidemiol Drug Saf2009，18，6： | 1 |
| 7 | QT-interval shortening in spontaneous reports submitted to the FDA:the need for consensus显示文摘 | Raschi E Poluzzi E Koci A | 2011 | Br J Clin Pharmaco2011，72，5： | 1 |
| 8 | QT-interval prolongation bynon-cardiac drugs:lessons to be learned from recent experience显示文摘 | De Ponti F Poluzzi E Montanaro N | 2000 | Eur J Clin Pharmacol2000，56，1： | 1 |
| 9 | QTc and psychotropic drugs显示文摘 | De Ponti F Poluzzi E Montanaro N | | 0，，： | 1 |
| 10 | Montanoro N QT interval prolongadon by cardiac or noncardiac factors显示文摘 | De Ponti F Poluzzi E | 2002 | Eur J Clin Pharmacol2002，57，1： | 1 |
| 11 | Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview显示文摘 | De Ponti F Poluzzi E Cavalli A | 2002 | Drug Saf2002，25，4： | 1 |
| 12 | Antibacterial macrolides: a drug class with a complex pharmacological profile显示文摘 | ABU-GHARBIEH E VASINA V POLUZZI E | 2004 | 50(3 ) : 211-2222004，50，3： | 1 |
| 13 | Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes:an overview显示文摘 | De Pi F Poluzzi E Cavalli A | 2002 | Drug Saf2002，25，4： | 1 |
| 14 | QT-interval prolongation by non-cardiac drugs:lessons to be learned from recent experience显示文摘 | De Ponti F Poluzzi E Montanaro N | 2000 | Eur J Clin Pharmacol2000，56，1： | 1 |
| 15 | Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers显示文摘 | Cavalli A Poluzzi E De Ponti F | 2002 | J Med Chem2002，45，18： | 1 |
| 16 | QT interval prolongation by non-cardiac drugs: lessons to be learned from recent experience显示文摘 | De Ponti F Poluzzi E Montanaro N | 2000 | Eur J Clin Pharmacol2000，56，1： | 1 |
| 17 | The hERG K+ channel: target and antitarget strategies in drugdevelopment显示文摘 | RASCHI E VASINA V POLUZZI E | 2008 | Pharmacol Res2008，57，3： | 1 |
| 18 | The hERG K+ channel:target and antitarget strategies in drug development显示文摘 | Rashi E Vasina V Poluzzi E | 2008 | Pharmacol Res2008，57，： | 1 |
| 19 | Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs:a call for consensus显示文摘 | Ponti F Poluzzi E Montanaro N | 2001 | Eur J Clin Pharmacol2001，57，3： | 1 |
| 20 | Toward a pharmacophore for drugs inducing the long QT syndrome:insights from a CoMFA study of HERG K+ channel blockers显示文摘 | Cavelli A Poluzzi E De Ponti F | 2002 | J Med Chem2002，45，18： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员